Dipraglurant
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.
primaryTopic
Dipraglurant
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.
has abstract
Dipraglurant (INN) (code name ...... of non-parkinsonian dystonia.
@en
ATC prefix
CAS number
872363-17-2
IUPAC name
6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine
@en
PubChem
thumbnail
Wikipage page ID
44,864,244
Wikipage revision ID
713,201,853
ChemSpiderID
25,069,676
molecular weight
2.65285e+2
smiles
c1ccncC#CCCc2cn3ccF
StdInChIKey
LZXMUJCJAWVHPZ-UHFFFAOYSA-N
hypernym
comment
Dipraglurant (INN) (code name ...... of non-parkinsonian dystonia.
@en
label
Dipraglurant
@en